6-K
Evogene Ltd. (EVGN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2022
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
CONTENTS
Attached hereto and incorporated by reference herein is the following exhibit:
| 99.1 | Lavie Bio Investor Presentation. |
|---|
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: February 14, 2022 | EVOGENE LTD.<br><br> (Registrant)<br><br> <br><br> By: /s/ Dorit Kreiner<br><br> Dorit Kreiner<br><br> Chief Financial Officer |
|---|
Exhibit 99.1
Lavie Bio Introduction February 2022
2 This presentation contains "forward-looking statements" relating to future events, and Lavie Bio (the “Company”) and its parent, Evogene Ltd. (“Evogene”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements.Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, product pipeline, future sales, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors mayaffect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in thispresentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. Forward looking statement
3 The forkinfluencesthe farm Healthierfood Sustainable environment Productive agriculture Bettervalue
4 Farmers around the world invest $200B annually in ag inputs to protect and nurture their crops $135B Chemical Fertilizers $55B Crop Protection Chemicals $10B Ag-Biologicals * The amounts described herein are based on company’s estimations
5 The Ag-Biologicals opportunityDriving healthier crops, sustainability and productive agriculture Driving cropproductivity to address consumer preferences: Faster Go-to-Market Fastest growingag. inputs segment Chemical Pesticides ~10-15 years | ~$250M Bio Pesticides ~5-8 years |
<$15M Time Cost 2015 2021E 2026F \*Source: Markets and Markets, industry publications; Reportlinker.com Wave 1 Wave 2 $3.2B $10.6B $18.5B Company estimations SustainableProtect from resistance developmentNew modesof action
6 The Ag-Biologicalsuntapped potential Crop Protection & Fertilizers Ag-BiologicalsToday Sustainability + +++ Efficacy +++ ++ Consistency +++ + Commercial viability +++ +
7 Our Mission Improve food quality, sustainabilityand agriculture productivity through microbiome based ag-biologicals technology and products
8 The Power of the Microbiome Billions of microbes make a difference! Billions of microbes integral to plant-related ecosystems impact the entire plant lifecycle Surrounding microbes generate nature’s largest ‘function bank’ to the plant growth and development These microbes act as the ‘Live Engine’ supporting yield production in the field The challenge: Discovering the right microbes and tailoring them for commercial use
9 Biology Driven Design platform The microbiome OS Discovery Billions > Promising few Optimization Promising few > Product Commercialization Product > Label Expansion 1 Lavie Bio holds an exclusive license to use Evogene’s MicroBoost AI tech engine for the discovery and development of products in Lavie Bio’s field of activity. 2 As part of Corteva’s investment in Lavie Bio in 2019, Lavie acquired the assets of Taxon Biosciences, including a large microbial collection. 1 2
10 Decoding the natural diversityof genetic functionality Function-based product discovery & tailoring Product CommercializationMaximized functionality Required Functions Product Requirements Lead Candidates OptimizationEnhanced functionality DiscoveryMin. Microbes Max. Functions Optimized Candidates Microbiomesamples Gene Pool ofMicrobiomes Function Catalogof Microbiome
Lavie BioNext generation Ag-Biologicals Sustainability + +++ +++ Efficacy +++ ++ +++ Consistency +++ + +++ Commercial viability +++ + +++ 11 Ag-BiologicalsToday Ag-Biologicals Next generation Crop Protection & Fertilizers
Product Program Product focus Application Target market* Potential expansion* Discovery Pre-Development Development Stage 1 Development Stage 2 Pre-Commercialization Product* Bio-Stimulants Seed treatment, Spring WheatNorth America 25M ACRES wheat North America 500M ACRES LAV213, LAV218Bio-stimulants 2 Seed treatmentCornNorth AmericaEurope 120M ACREScorn US, EU 180M ACRES >2025 Bio-Pesticides LAV311, LAV312 2 Fruit rots FoliarFruits & VegEuropeNorth America <$200M grapes chemicals usage +$800MAdditional Fruits & Veg 2024 LAV321, LAV322Downey mildew FoliarFruits & VegEuropeNorth America <$350M grapes chemicals usage +$150MAdditional Fruits & Veg 2025 LAV431, LAV432Seedling disease(Pythium) Seed Treatment,Corn, soy, F&VNorth AmericaEurope <$500M <$200M >2025 LAV441, LAV442Bio-Insecticides Seed Treatment,Corn, foliar soyNorth AmericaEurope <$1.5B existing traits and chemicals market <$500M >2025 Lavie Bio product pipeline * Company estimations 2022 1 1 More info on slide 132 More info on slide 14 12
13 Bio-stimulants driving yield advantage Untreated 2022 2023- 2024* USA - ND USA - ND, MT Canada - Sasc. Man. AB. Better than Bio-stimulants benchmarks tested Sales in North America initiated in 2022 2% 1% 3% 4% 5% Other Ag-Biologicals Yield improvement (%) *Expected geographic expansion
14 Bio-fungicides against Botrytis& fruit rots LAV311 & LAV312 Untreated LAV Better than ag-biologicals and potentially comparable to chemical benchmarks tested Expected launch in North America in 2024 60% 40% 20% 0% Other ChemicalsControl LAV A B A Different letters indicate significant differences between groups (p values<0.05) Rot reduction (%) Other Ag-BiologicalsControl
15 Established ‘End to End’ capabilities Confidential 15
16 Business Model Direct model Lavie Bio Product End-to-end product developmentCommercialization through direct channelsRevenues from sales Collaboration model Lavie Bio ‘tech-inside’ product Joint product developmentCommercialization through partner’s channelsRevenues from R&D / milestone payments and royalties,
17 Strategic partners & shareholders 28% 72%
We’ve gotthe right team to nurture it Management Team Board of Directors Dotan Borenstein |
CBO Leadership experience of 25+ years in business development, strategic management Michael Ionesco| VP Research Innovative research leader with deep biotechnology, big data and informatics expertise Dorit Kriener | CFO 20+ years of
experience in corporate finance, public and private fundraising, strategy and accounting management Amir Bercovitz| VP Development Extensive development and product expertise in the ag-biologicals field for 30+ years – led introductions of 5
commercial products James Presnail | COO Russel Putland | VP commercial Ofer Haviv Chairman of the board, Evogene President & CEO Kristian Bjorneboe Seasoned business development leader Frederic C. Beudot Global Portfolio Leader for
Biologicals at Corteva Agriscience™ Trevor Thiessen Senior agriculture executive, experienced in marketing, sales, and go-to-market 30+ years of ag commercial leadership roles with ‘ground up’ experience in large multi-national
organizations 25+ years broad industrial experience serving in leadership roles of complex agricultural product programs management 18
19 Milestone Roadmap Bio-stimulant for wheat ‘result™’ product sales expansion to MT, MN and Canada for spring wheatBio-stimulant for wheat ‘result™’ label expansion Downy mildew bio-fungicides File for regulatory approval for leading product candidates LAV321 or LAV322 Additional product launch 2022 2023-2024 Bio-stimulant for wheat initial product sales of ‘result™’ for spring wheat Fruit rot bio-fungicides Product candidate advancement in regulation process for LAV311
Thank you!